Table 2—

Changes in routine laboratory and examination data over the course of the study

Metformin
Gliclazide
Pioglitazone
StartEndStartEndStartEnd
HbA1c8.04 ± 0.96.9 ± 0.5*7.85 ± 0.96.64 ± 0.5*7.43 ± 0.96.62 ± 0.5*
Mean change in HbA1c1.12 ± 0.841.21 ± 0.820.81 ± 0.63
Fasting glucose9.77 ± 2.37.3 ± 1*10.1 ± 2.17.4 ± 1.4*9.45 ± 2.16.8 ± 1.1*
BMI (kg/m2)29.2 (28.1–31.6)28.6 (27.3–30.4)28.7 (28.3–34.4)30.6 (28–35.7)30.6 (29.4–35.2)32.1 (29.8–37)
Cholesterol (mg/dl) [mmol/l]217.9 ± 28.2 [5.63 ± 0.73]203.8 ± 35.3* [5.27 ± 0.91]207.1 ± 32.2 [5.35 ± 0.83]198.5 ± 35.3 [5.13 ± 0.91]208.8 ± 29.7 [5.40 ± 0.77]210.7 ± 31.6 [5.44 ± 0.82]
Triglyceride (mg/dl) [mmol/l]202 ± 110 [2.28 ± 1.24]175.6 ± 114.4 [1.98 ± 1.29]157 ± 93.14 [1.77 ± 1.05]167.6 ± 94 [1.90 ± 1.06]203 ± 149 [2.29 ± 1.68]176 ± 115 [2.00 ± 1.30]
HDL cholesterol (mg/dl) [mmol/l]48.7 ± 9.4 [1.26 ± 0.24]46.8 ± 8.5 [1.21 ± 0.22]49.5 ± 9.8 [1.30 ± 0.25]48.3 ± 10.1 [1.24 ± 0.26]49.6 ± 11.8 [1.28 ± 0.30]52.7 ± 11.1 [1.36 ± 0.29]
ApoB (mg/dl)98.2 ± 12.590.4 ± 15.8*90.8 ± 20.487.2 ± 21.692.6 ± 15.389.1 ± 16.2
Cholesterol-to-HDL ratio4.62 ± 1.014.49 ± 1.054.46 ± 1.174.34 ± 1.74.5 ± 1.34.23 ± 1.19
Cholesterol-to-apoB ratio2.22 ± 0.152.26 ± 0.182.39 ± 0.52.36 ± 0.462.28 ± 0.252.39 ± 0.26*
  • Data are means ± SD, except BMI, which is median (interquartile range).

  • *

    * P < 0.01 within-group end versus start;

  • P < 0.05 within-group end versus start;

  • P = 0.06 within-group end versus start.